Italia Markets closed

Esperion Therapeutics, Inc. (0IIM.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
7,05+0,31 (+4,57%)
Alla chiusura: 04:33PM BST
Schermo intero
Chiusura precedente6,74
Aperto7,15
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno7,05 - 7,15
Intervallo di 52 settimane7,05 - 7,15
Volume215
Media VolumeN/D
Capitalizzazione228,418M
Beta (5 anni mensile)0,33
Rapporto PE (ttm)N/D
EPS (ttm)-5,22
Prossima data utili31 ott 2022 - 04 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Esperion to Participate in Upcoming September Investor Conferences

    ANN ARBOR, Mich., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at Morgan Stanley’s 20th Annual Global Healthcare Conference and also participate in H.C. Wainwright’s Annual Global Investment Conference. Event:Morgan Stanley 20th Annual Global Healthcare ConferenceDate:Monday, September 12th, 2022Time:9:20 AM (ET)Format:Presentation and 1:1 MeetingsWebcast:Link Event:H.C. Wainwright Annual Global Investment Conferen

  • GlobeNewswire

    Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

    ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD) by the American College of Cardiology (ACC) task force on expert consensus decision pathways (ECDP). The recommendation, an update to the 2017 ECDP, was released on August 25, 2022 and published online in the Jou

  • GlobeNewswire

    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 2, 2022, the Compensation Committee of Esperion’s Board of Directors granted 13 new employees 66,000 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fid